Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
RESEARCH TOOLSreports
Holding PHAT?
Track your performance easily
PHAT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.07 - $19.71
Previous CloseN/A
Volume285.74K
Average Volume (3M)1.01M
Market Cap
$471.80M
Enterprise Value$1.35B
Total Cash (Recent Filing)$879.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Mar 04, 2025EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.69
Shares Outstanding68,377,380
10 Day Avg. Volume1,019,978
30 Day Avg. Volume1,012,783
Standard Deviation0.21
R-Squared0.02
Alpha-0.00610
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)17.96
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market Cap2.87
Enterprise Value/Revenue51.50
Enterprise Value/Gross Profit2.63K
Enterprise Value/Ebitda-4.68
Forecast
1Y Price Target
$28.00Price Target Upside341.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Phathom Pharmaceuticals News
PremiumCompany Announcements
Phathom Pharmaceuticals Reports Significant Revenue Growth
Bulls Say, Bears Say
Bulls Say
Commercial SuccessAchieving coverage with the three largest pharmacy benefit managers and over 120M commercial lives covered with greater than 80% commercial coverage represents significant progress for Voquezna.
Market PotentialVoquezna's blockbuster opportunity in GERD and potential for displacing standard PPI limitations are supported by labeling that explicitly defines Voquezna’s superiority in erosive GERD healing and maintenance of healing compared to traditional lansoprazole PPI therapy.
Regulatory AdvantageThe full 10-year New Chemical Entity exclusivity could apply broadly to VOQUEZNA tablet products with patent protection to May 3, 2032, providing potential protection from generic competition.
Bears Say
Product ConcernsIncreased concerns around a potentially shorter than expected IP for Voquezna drove underperformance.
Regulatory IssuesThe issue with the FDA process is expected to continue being an overhang, putting pressure on PHAT shares.
Stock PerformancePHAT shares underperformed in 2024 compared to the XBI and the S&P500.
---
Ownership Overview
18.29% Insiders
15.59% Mutual Funds
0.11% Other Institutional Investors
57.48% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PHAT FAQ
What was Phathom Pharmaceuticals’s price range in the past 12 months?
Phathom Pharmaceuticals lowest stock price was $6.07 and its highest was $19.71 in the past 12 months.
What is Phathom Pharmaceuticals’s market cap?
Phathom Pharmaceuticals’s market cap is $471.80M.
When is Phathom Pharmaceuticals’s upcoming earnings report date?
Phathom Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 32 days.
How were Phathom Pharmaceuticals’s earnings last quarter?
Phathom Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -$1.32 earnings per share for the quarter, beating the consensus estimate of -$1.469 by $0.149.
Is Phathom Pharmaceuticals overvalued?
According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued.
Does Phathom Pharmaceuticals pay dividends?
Phathom Pharmaceuticals does not currently pay dividends.
What is Phathom Pharmaceuticals’s EPS estimate?
Phathom Pharmaceuticals’s EPS estimate is -1.21.
How many shares outstanding does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 68,377,380 shares outstanding.
What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?
Phathom Pharmaceuticals reported an EPS of -$1.32 in its last earnings report, beating expectations of -$1.469. Following the earnings report the stock price went up 2.778%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals?
Among the largest hedge funds holding Phathom Pharmaceuticals’s share is Woodline Partners LP. It holds Phathom Pharmaceuticals’s shares valued at 47M.
---
Phathom Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.00 (341.64% Upside)
$28.00 (341.64% Upside)
Blogger Sentiment
Bullish
PHAT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $160.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.90%
12-Months-Change
Fundamentals
Return on Equity
181.41%
Trailing 12-Months
Asset Growth
63.32%
Trailing 12-Months
Company Description
Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.
---
PHAT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Phathom Pharmaceuticals demonstrated strong commercial and financial performance in Q3 2024, marked by the successful launch and rapid adoption of VOQUEZNA, significant revenue growth, and financial stability. However, the company also faced increased SG&A expenses and reported a net loss, although these were anticipated investments tied to their strategic initiatives.Read More>---
PHAT Stock 12 Month Forecast
Average Price Target
$28.00
▲(341.64% Upside)
Technical Analysis
Ironwood Pharma
―
Supernus Pharmaceuticals
―
Vertex Pharmaceuticals
―
AbbVie
―
RedHill Biopharma
―
Best Analysts Covering PHAT
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
+4.58%
assigned a buy rating 2 months ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of +4.58% per trade.
---